HEMATOLOGIST IN MEDICAL ONCOLOGY
Job Opportunity:
The Department of Oncology, Cancer Care Alberta, Division of Medical Oncology at the Cross Cancer Institute (CCI), with Alberta Health Services is accepting applications for a full-time Hematologist/Medical Oncologist with expertise/training in management of lymphoma and myeloma.
This position is based at the Cross Cancer Institute (CCI) in Edmonton. The successful applicant will join a team of multidisciplinary cancer programs and a team of Medical and Radiation Oncologists, Nurse Practitioners and other medical support staff in the Edmonton and North zones. They are expected to work with the translational science team. Responsibilities will include participation in ambulatory clinics for patients with lymphoproliferative disorders, and attending duties on the inpatient lymphoma/myeloma/autologous stem cell transplant unit at CCI. Other responsibilities will include participation in local and provincial tumour team based activities including clinical case reviews at tumour board rounds, annual, provincial tumour team meetings and local quality assurance and quality improvement initiatives.
Additionally, there is a leadership opportunity as a myeloma program lead. Candidate will have an appointment in the Department of Oncology, University of Alberta, and will be expected to commit 30% of their time in clinical research and teaching activities within the Department. CCI, Edmonton operates within a provincial framework for cancer care supported by provincial clinical guidelines and standards, focused on patient centered care.
Qualifications include an MD, certification in Internal Medicine, special competency in Medical Oncology/ Hematology (or equivalent), additional specialized training and experience in Malignant Hematology and eligibility for licensure in the Province of Alberta.
Candidates should have additional specialized training in the area of malignant lymphoid disease, as well as training and experience with cell therapy (BMT and CarT). Familiarity with early drug development/phase1 would be an asset.